New drug combo aims to boost immune response in hard-to-treat cancers
NCT ID NCT05913388
First seen Apr 23, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study tests whether adding an experimental drug (GB1211) to the standard immunotherapy pembrolizumab can shrink tumors better than pembrolizumab alone. It includes about 92 adults with advanced melanoma or head and neck cancer that has spread or cannot be removed. Participants will receive either the combination or pembrolizumab with a placebo, and researchers will monitor tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.